Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Thomas Goldner"'
Autor:
Debra C. Quenelle, Thomas Goldner, Alexander Birkmann, Tamara Pfaff, Holger Zimmermann, Terri L. Rice, Mark N. Prichard, Deborah J. Collins, Susanne Bonsmann
Publikováno v:
Antiviral Research. 149:1-6
Pritelivir, a helicase-primase inhibitor, has excellent in vitro and in vivo activity against human herpes simplex virus (HSV). Mice lethally infected with HSV type 1 or 2, including acyclovir-resistant strains, were treated 72 h after infection for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10120bfa283164eed57cc592845c456c
https://doi.org/10.1016/j.antiviral.2017.11.002
https://doi.org/10.1016/j.antiviral.2017.11.002
Autor:
Lars Steinbrueck, Karen Wagner, Martin Messerle, Thomas Goldner, Peter Lischka, Sebastian Neuber, Eva Maria Borst
Human cytomegalovirus (HCMV) genome encapsidation requires several essential viral proteins, among them pUL56, pUL89, and the recently described pUL51, which constitute the viral terminase. To gain insight into terminase complex assembly, we investig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::314b96f26e49eddc2922a64a07d1cc4d
https://europepmc.org/articles/PMC5446633/
https://europepmc.org/articles/PMC5446633/
Autor:
Thomas Goldner, Craig A. Magaret, Susanne Stoelben, Burkhard Timmler, Alexander Birkmann, Lawrence Corey, Holger Zimmermann, Anna Wald, Kurt Diem, Jia Jin Kee, Paul T. Edlefsen, Helga Ruebsamen-Schaeff, Meei Li Huang, Terri Warren
Publikováno v:
The Journal of Infectious Diseases
Pritelivir (also known as BAY 57–1293 and AIC316) belongs to a new class of antiviral compounds, the helicase-primase inhibitors (HPIs), that prevent the de novo synthesis of virus DNA through inhibition of the helicase-primase complex [1]. Functio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::127735b538d367e57cab8a7735251865
https://pubmed.ncbi.nlm.nih.gov/27056950
https://pubmed.ncbi.nlm.nih.gov/27056950
Autor:
Holger Zimmermann, Thomas Goldner, Daniela Paulsen, Tobias Wunberg, Judith Baumeister, Peter Lischka, Guy Hewlett, Helga Ruebsamen-Schaeff
Publikováno v:
Antimicrobial Agents and Chemotherapy. 54:1290-1297
Human cytomegalovirus (HCMV) remains a serious threat for immunocompromised individuals, including transplant recipients and newborns. To date, all drugs licensed for the treatment of HCMV infection and disease target the viral DNA polymerase. Althou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0152783584c1c80055bade5015fcd36
https://doi.org/10.1128/aac.01596-09
https://doi.org/10.1128/aac.01596-09
Publikováno v:
Antiviral research. 116
Letermovir is a new drug in Phase 3 clinical development for the prevention of human Cytomegalovirus (HCMV) infections in hematopoietic-stem-cell transplant recipients (HSCT). In contrast to marketed anti-HCMV drugs which all target the viral DNA pol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2635ec73d2fa5caf059682ac7217cb88
https://pubmed.ncbi.nlm.nih.gov/25637709
https://pubmed.ncbi.nlm.nih.gov/25637709
Autor:
Soumi Sukla, Thomas Goldner, Holger Zimmermann, Alexander Birkmann, Hugh J. Field, Daniela Paulsen, Helga Ruebsamen-Schaeff, André Welbers, Dirk Kropeit, Subhajit Biswas
Publikováno v:
Antimicrobial agents and chemotherapy. 58(7)
Herpes simplex virus (HSV) infections can cause considerable morbidity. Transmission of HSV-2 has become a major health concern, since it has been shown to promote transmission of other sexually transmitted diseases. Pritelivir (AIC316, BAY 57-1293)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d667cfb27636682b647939806e619c2b
https://pubmed.ncbi.nlm.nih.gov/24752278
https://pubmed.ncbi.nlm.nih.gov/24752278
Letermovir is a novel antiviral compound currently in clinical development for the prevention of human cytomegalovirus (HCMV) infections. In contrast to all currently approved anti-HCMV drugs that target the viral DNA polymerase, letermovir acts via
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95d99bba0e4cba19461badc33b97800f
https://europepmc.org/articles/PMC3910730/
https://europepmc.org/articles/PMC3910730/
Autor:
Holger Zimmermann, Helga Ruebsamen-Schaeff, Guy Hewlett, Thomas Goldner, Peter Lischka, Nicole Ettischer
Human cytomegalovirus (HCMV) remains the leading viral cause of birth defects and life-threatening disease in transplant recipients. All approved antiviral drugs target the viral DNA polymerase and are associated with severe toxicity issues and the e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d697ad032270e79a1ff6419b595cb73
https://europepmc.org/articles/PMC3187482/
https://europepmc.org/articles/PMC3187482/
Autor:
Helga Ruebsamen-Schaeff, Thomas Goldner, Daniela Paulsen, Holger Zimmermann, Tobias Wunberg, Judith Baumeister, Peter Lischka, Guy Hewlett
Publikováno v:
Antiviral Research. 86:A23
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::602b4f5d7c80c9b0d8990d26cc4fec1e
https://doi.org/10.1016/j.antiviral.2010.02.343
https://doi.org/10.1016/j.antiviral.2010.02.343
Autor:
Tamás Vermes, Mark Kielpinski, Thomas Henkel, Miquel A. Pericàs, Esther Alza, Angelica Corcuera, Helmut Buschmann, Thomas Goldner, Andreas Urban
Publikováno v:
Analytical Methods
A fully automated microfluidic system was developed to screen for novel anti-HBV capsid assembly modulators. High-resolution dose–response curves were generated using convection-dominated Taylor–Aris dispersion of the screening compounds.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7b60143c556826395c038e5eb226ba7